Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
暂无分享,去创建一个
D. Carbone | T. Shukuya | T. Nakatsura | S. Kitano | T. Okimoto | J. Amann | D. Ikarashi | S. Sinicropi-Yao | H. Onagi | T. Hayashi
[1] I. Ulasov,et al. Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. , 2021, Brain : a journal of neurology.
[2] J. Galon,et al. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.
[3] C. Brennan,et al. Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.
[4] B. Becher,et al. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes , 2020, Cell.
[5] T. Isobe,et al. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells , 2020, Cancer science.
[6] N. Hanna,et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Jeffrey E. Lee,et al. B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.
[8] Yanhui Liu,et al. Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer , 2020, OncoTargets and therapy.
[9] E. Sato,et al. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports , 2019, BMC Cancer.
[10] Yong Gu,et al. PD-1 Expression and Function of T-Cell Subsets in TILs From Human Lung Cancer , 2019, Journal of immunotherapy.
[11] L. Hansen,et al. Stereotactic Radiosurgery With and Without Checkpoint Inhibition for Patients with Metastatic Non-Small Cell Lung Cancer to the Brain: A Matched Cohort Study , 2019, Neurosurgery.
[12] J. Huse,et al. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. , 2019 .
[13] M. Harada,et al. Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity , 2019, Cancer science.
[14] T. Yamanaka,et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.
[15] Joe Y. Chang,et al. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment , 2019, Front. Immunol..
[16] H. Nishikawa,et al. Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.
[17] John T. Poirier,et al. NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.
[18] Yi-long Wu,et al. Stromal PD‐L1–Positive Regulatory T cells and PD‐1–Positive CD8‐Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD‐1/PD‐L1 Blockade Immunotherapy , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] C. Bettegowda,et al. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.
[20] T. Isomura,et al. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. , 2017, Human pathology.
[21] H. Iwata,et al. Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer , 2017, Oncotarget.
[22] F. Aversa,et al. Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value , 2017, Clinical Cancer Research.
[23] Betty Y. S. Kim,et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] K. Patel,et al. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases , 2017, American journal of clinical oncology.
[25] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[26] Young A Kim,et al. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. , 2017, European journal of cancer.
[27] Ralph R. Weichselbaum,et al. Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.
[28] Betty Y. S. Kim,et al. Immune Priming of the Tumor Microenvironment by Radiation. , 2016, Trends in cancer.
[29] L. Zitvogel,et al. Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.
[30] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[31] Gwénaël Le Teuff,et al. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Nishikawa,et al. Roles of regulatory T cells in cancer immunity. , 2016, International immunology.
[33] J. Stebbing,et al. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy , 2016, Oncoimmunology.
[34] Xiaozhen Liu,et al. Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis , 2016, Oncotarget.
[35] M. Hattori,et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.
[36] Chuan-miao Xie,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer , 2016, Oncotarget.
[37] H. Heinzl,et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases , 2016, Oncoimmunology.
[38] Bernard A. Fox,et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma , 2015, Journal of Immunotherapy for Cancer.
[39] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[40] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[41] H. Ditzel,et al. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[42] Chichung Wang,et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.
[43] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[44] P. Ellis,et al. Brain metastases in non-small-cell lung cancer. , 2014, Clinical lung cancer.
[45] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[46] J. Kuratsu,et al. Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas , 2008, The Journal of pathology.
[47] T. Dønnem,et al. Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[48] A. Young,et al. Treatment for patients with cerebral metastases. , 1978, Archives of neurology.
[49] F. Jamali,et al. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.